ライフサイエンスコーパス: calicheamicin

1 ber of the nonchromoprotein enediyne family, calicheamicin.

2 al antibody conjugated to a cytotoxic agent, calicheamicin.

3 dy linked to the potent antitumor antibiotic calicheamicin.

4 aked DNA was markedly different from that of calicheamicin.

5 a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent.

6 a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent.

7 rase CalG4, provides growing support for the calicheamicin aminopentose pathway as a TDP-sugar-depend

8 prior studies on the base specificity of the calicheamicin aminopentosyltransferase CalG4, provides g

9 ependent increase in M1G in DNA treated with calicheamicin and bleomycin, oxidizing agents known to p

10 Other conjugates of calicheamicin and conjugates of potent tubulin poisons (

11 A cleavage by naturally occurring enediynes [calicheamicin and esperamicin), non-enediyne small molec

12 tic oligosaccharide moiety of the antibiotic calicheamicin and the head-to-head dimer of this oligosa

13 ns, more than 70 differentially glycosylated calicheamicin and vancomycin variants are reported.

14 stinct natural product biosynthetic pathways-calicheamicin and vancomycin-readily catalyze reversible

15 CD22 monoclonal antibody [mAb] conjugated to calicheamicin) and its in vivo use to characterize the k

16 nti-CD22 monoclonal antibody conjugated with calicheamicin [anti-CD22/cal]) efficiently depleted B ce

17 y be a key precursor to the enediyne core of calicheamicin, as it is the only programmed, enzyme-boun

18 We now present evidence that calicheamicin bends its DNA targets.

19 8, the polyketide synthase (PKS) involved in calicheamicin biosynthesis, facilitating the unambiguous

20 some insight into the elusive early steps of calicheamicin biosynthesis.

21 udy of the UGDH homolog CalS8 encoded by the calicheamicin biosynthetic gene is reported and represen

22 ng an intercalating anthranilate moiety, and calicheamicin, both groove binders, were found to cleave

23 irs in Escherichia coli; (ii) the C-1027 and calicheamicin cognate PKSE-TEs in Streptomyces lividans

24 Consistent with previous observations, calicheamicin damage at the 3'-end of a purine tract (po

25 s containing AGGA and ACAA binding sites for calicheamicin did not possess intrinsic curvature.

26 3-targeted immunoconjugate of N-acetyl-gamma-calicheamicin dimethyl hydrazide [CalichDMH], a potent D

27 eptin) and three from 10-membered producers (calicheamicin, dynemicin, and esperamicin), reveals a cl

28 It was also observed that binding of calicheamicin epsilon to a 273 bp construct with phased

29 Binding of calicheamicin epsilon, the aromatized form of the parent

30 rgeted chemotherapy with immunoconjugates of calicheamicin, exemplified by gemtuzumab ozogamicin (Myl

31 ies specific for tumour-associated antigens, calicheamicin exerts strong antigen-specific anti-tumour

32 Calicheamicin gamma 1 (1) was found to be less efficient

33 (T-C-C-T).(A-G-G-A) sequence as a preferred calicheamicin gamma 1I binding site and established the

34 Calicheamicin gamma 1I binds to the DNA minor groove wit

35 Calicheamicin gamma 1I binds to the minor groove of the

36 Calicheamicin gamma 1I is an enediyne antibiotic possess

37 Sequence-specific binding of calicheamicin gamma 1I to the (T-C-C-T).(A-G-G-A) contai

38 ther enediynes, such as neocarzinostatin and calicheamicin gamma 1I under similar reaction conditions

39 We report on the solution structure of the calicheamicin gamma 1I-DNA hairpin duplex complex contai

40 ed in this article: endiandric acids (1982), calicheamicin gamma(1)(I) (1992), Taxol (1994), and brev

41 nthetic enzymes for the 10-membered enediyne calicheamicin gamma(1)(I), including the elusive beta-ke

42 n epsilon, the aromatized form of the parent calicheamicin gamma(1)(I), to oligonucleotide constructs

43 e enediyne antibiotics, neocarzinostatin and calicheamicin gamma(1)(I), was exploited in control stud

44 that facilitates cellular uptake of a toxic calicheamicin-gamma(1) derivative, induces complete remi

45 D33 antibody to facilitate uptake of a toxic calicheamicin-gamma(1) derivative.

46 r to facilitate cellular uptake of the toxic calicheamicin-gamma(1) derivative.

47 induced by GO, and, to a lesser degree, free calicheamicin-gamma(1).

48 We demonstrate here that the enediyne calicheamicin gamma1I, a strand-breaking agent specific

49 phore of (DA) and the carbohydrate domain of calicheamicin gamma1I.

50 A damage produced by the enediyne antibiotic calicheamicin gammaII in nucleosomes reconstituted onto

51 Here, we report structures of all four calicheamicin glycosyltransferases (CalG1, CalG2, CalG3,

52 gamicin, a CD22 monoclonal antibody bound to calicheamicin, has resulted in marrow CR rates of 55% an

53 lishes CalE10 as the key oxidase involved in calicheamicin hydroxylamino glycoside formation.

54 Phase I trials of a calicheamicin immunoconjugate for treatment of acute mye

55 ences and the effects of DNA conformation on calicheamicin-induced DNA cleavage suggest that sequence

56 Calicheamicin is a hydrophobic enediyne antibiotic that

57 Calicheamicin is a potent cytotoxic agent that causes do

58 conjugate of an anti-CD33 antibody linked to calicheamicin, is effective monotherapy for CD33(+) rela

59 Comparison of the calicheamicin locus with the locus encoding the chromopr

60 mage produced by esperamicin C, an analog of calicheamicin missing the terminal sugar-aromatic ring i

61 gamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in patients wi

62 The discovery of the heptaene in the calicheamicin system promotes a more convergent model fo

63 (GO) is an immunoconjugate between CD33 and calicheamicin that is internalized when binding to the e

64 the hypothesis that the preferred targets of calicheamicin, the 3' ends of oligopurine tracts, are ch

65 ere, we describe the first successful use of calicheamicin theta(I)1 for targeted chemotherapy in a c

66 el, rationally designed enediyene antibiotic calicheamicin theta(I)1 of exceptionally high cytotoxic

67 Given the sensitivity of calicheamicin to local DNA conformation, this observatio

68 Calicheamicin unexpectedly caused 1'-oxidation at a low